IUSM Alzheimer's Disease Drug Discovery Center: PTC Software

IUSM 阿尔茨海默病药物研发中心：PTC 软件

• 批准号: 10198429
• 负责人: Bruce T Lamb
• 金额: $ 39.37万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-30 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10198429
• 关键词: Alzheimer disease prevention; Alzheimer' s Disease; Alzheimer' s disease model; Animal Disease Models; Award; Basic Science; Biological Markers; Biology; Cause of Death; Clinical Sciences; Computer software; Data; Disease; Funding; Genetic; Goals; Human Pathology; Indiana; Institutes; Intervention; Investments; Lead; Methods; Mission; Parents; Patients; Pharmacologic Substance; Postdoctoral Fellow; Research Personnel; Science; Scientist; Technology; Therapeutic; Translational Research; United States; United States National Institutes of Health; Universities; Validation; Work; base; data sharing; design; disability; drug development; drug discovery; flexibility; medical schools; novel; pre-clinical; sharing platform; translational study

Project Summary Overall: The strategic goal of the Indiana University School of Medicine (IUSM) Alzheimer’s Disease Drug Discovery (ADDD) Center is to integrate sophisticated capability for early drug discovery and contribute to a broader study of emerging Alzheimer’s Disease target hypotheses with the goal of generating new classes of potential therapeutics. The ADDD CENTER will establish itself as a strategic and operational partner for the NIA AMP-AD and MODEL-AD initiatives. By design, this will provide drug discovery capability to bridge the work in target discovery (AMP-AD) with newly discovered lead molecules characterized in AD animal models based on human pathology, genetics and translational biomarkers (MODEL-AD). To accomplish the mission of the ADDD CENTER, we have assembled a team of scientists from Indiana University, Purdue University, and the Indiana Clinical and Translational Sciences Institute (CTSI). This team has considerable expertise in Alzheimer’s disease biology, CNS pharmaceutical drug discovery and development, and scientific excellence in the core discovery technologies that will drive the ADDD CENTER’s contributions and deliverables. A key advantage and differentiated strength of the proposed ADDD CENTER is the primary scientific coordination and administration through IUSM. Specific Aims are: 1. Create a portfolio of characterized AD drug discovery targets representing novel intervention hypotheses that capitalizes on significant investments in basic research and emerging disease understanding. 2. Perform advanced pre-clinical target validation and enablement studies to prioritize the best opportunities for therapeutic discovery. 3. Create quality and well characterized Lead molecules for targets that meet milestone criteria and are opportunities for further translational investment. 4. Create a flexible data sharing platform to enable global researchers with data and Target Enablement Packages to expand on the work of the ADDD CENTER.

项目概要 总体：印第安纳大学医学院 (IUSM) 的战略目标 阿尔茨海默病药物研发 (ADDD) 中心将整合先进的 早期药物发现的能力，并有助于更广泛的新兴药物研究 阿尔茨海默氏病的目标假设是产生新的类别 潜在的治疗方法。 ADDD中心将把自己打造成一个战略性和 NIA AMP-AD 和 MODEL-AD 计划的运营合作伙伴。根据设计，这将 提供药物发现能力，将靶点发现 (AMP-AD) 工作与 新发现的先导分子在基于人类的 AD 动物模型中得到表征 病理学、遗传学和转化生物标志物（MODEL-AD）。 为了完成 ADDD CENTER 的使命，我们组建了一支团队 来自印第安纳大学、普渡大学和印第安纳临床医学中心的科学家 转化科学研究所（CTSI）。该团队在以下方面拥有丰富的专业知识 阿尔茨海默病生物学、中枢神经系统药物发现和开发、 核心发现技术的科学卓越将推动 ADDD CENTER 的贡献和可交付成果。关键优势和差异化实力 拟议的 ADDD 中心是主要的科学协调和 通过 IUSM 进行管理。具体目标是： 1. 创建一系列特征性 AD 药物发现靶点，代表 利用重大投资的新颖干预假设 基础研究和新发疾病的了解。 2. 进行先进的临床前目标验证和启用研究 优先考虑治疗发现的最佳机会。 3. 为满足以下要求的目标创建高质量且特征明确的先导分子 里程碑标准，也是进一步转化投资的机会。 4、打造灵活的数据共享平台，让全球研究人员拥有数据 和目标支持包以扩展 ADDD 中心的工作。